[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467709":3},{"organization":4,"outcomesModule":7,"designInfo":24,"detailedDescription":27,"studyPopulation":28,"armGroups":29,"interventions":39,"overallOfficials":45,"centralContacts":49,"locations":55,"responsibleParty":74,"collaborators":76,"id":79,"slug":23,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":23,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":23,"enrollmentInfo":87,"targetDuration":23,"studyType":90,"phases":23,"briefSummary":91,"conditions":92,"keywords":95,"overallStatus":97,"whyStopped":23,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Immunis.AI","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":23},[9],{"measure":10,"description":11,"timeFrame":12},"Primary Aim","To determine if differential gene expression between peripheral blood phagocytic and non-phagocytic immune cells can distinguish breast cancer patients from cancer-negative controls.","12 months",[14,17,20],{"measure":15,"description":16,"timeFrame":12},"Secondary Aim 1","To evaluate minimal residual disease with a potential signature for breast cancer detection following curative therapy to evaluate the degree to which the original signature has changed.",{"measure":18,"description":19,"timeFrame":12},"Secondary Aim 2","To determine the sample size required to develop and validate a computational immunogenomic model capable of predicting the various types, grades, and stages of breast cancer.",{"measure":21,"description":22,"timeFrame":12},"Secondary Aim 3","To determine the temporal relation between biopsy procedures and signal strength or dilution.",null,{"allocation":23,"interventionModel":23,"interventionModelDescription":23,"primaryPurpose":23,"observationalModel":25,"timePerspective":26,"maskingInfo":23},"CASE_CONTROL","PROSPECTIVE","Efficient next generation RNA sequencing platforms have allowed for whole genome expression profiling of individual populations of immune cells as a novel means of searching for patterns of gene expression to aid in the identification of meaningful signals unique to various disease states. Single cell sequencing techniques have provided additional information useful in deconvolution strategies applied to model development on purified populations of immune cells. Recent interest in peripheral leukocyte subset gene expression profiles suggests that diagnostic information for many disorders may be contained therein. Mononuclear phagocytic cells including the various CD14+ subsets have been studied extensively in various disease states including some solid tumors. Previous large clinical studies at Immunis.AI have determined that transcriptomic profiles of CD14+ cell populations subtraction normalized from CD2+ cell populations were associated with aggressive disease phenotypes such as prostate cancer. Tumor heterogeneity, multifocality, and oligoclonality have been a significant barrier to development of meaningful tissue based multigene signatures for predicting cancer biologic behavior. The findings at Immunis.AI strongly suggest that analysis of RNA expression data from the body's immune surveillance cells has the potential to summarize the entire heterogeneous tumor. The investigators believe that the CD14\u002FCD2 log ratio can be understood as a subtraction normalization of gene expression which yields superior signal of early-stage cancer.","Patients presenting to the Duke Cancer Center for evaluation by Medical or Surgical Oncology of a newly diagnosed breast cancer Patients presenting to Duke Radiology for routine screening mammogram",[30,35],{"label":31,"type":23,"description":32,"interventionNames":33},"Controls: Patients with negative screening MMG","Patients presenting to Duke Radiology for routine screening mammogram will be screened for eligibility as negative controls. Study enrollment for negative controls presumes that patients do not receive their screening mammography results immediately. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.",[34],"Diagnostic Test: Blood test",{"label":36,"type":23,"description":37,"interventionNames":38},"Cases: Patients with known cancer diagnosis","Patients presenting to the Duke Cancer Center for evaluation by Medical or Surgical Oncology of a newly diagnosed breast cancer will be screened for study eligibility and approached, enrolled, and consented accordingly. Patients will be approached on the day of their first new patient visit to the Duke Cancer Center. If they are willing, they will be consented in clinic, and directed down to the lab for their first blood draw.",[34],[40],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":23},"DIAGNOSTIC_TEST","Blood test","Proprietary immunogenomic signature from peripheral blood CD14 and CD2 cells.",[36,31],[46],{"name":47,"affiliation":5,"role":48},"Kirk Wojno, MD","PRINCIPAL_INVESTIGATOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":23,"email":54},"Amanda Nash","CONTACT","855-855-6484","amanda.nash@duke.edu",[56],{"facility":57,"status":23,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Duke University","Durham","North Carolina","27710","United States","US",{"type":64,"coordinates":65},"Point",[66,67],-78.89862,35.99403,{"lat":67,"lon":66},[70,71,72],{"name":51,"role":52,"phone":53,"phoneExt":23,"email":23},{"name":51,"role":52,"phone":23,"phoneExt":23,"email":23},{"name":73,"role":48,"phone":23,"phoneExt":23,"email":23},"Shelley Hwang, MD",{"type":75,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR",[77],{"name":57,"class":78},"OTHER","100467709",false,"NCT05370300","SNAPS Breast Cancer Patient Study Breast Cancer Patients","Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance","Inclusion Criteria:\n\n* Patients \\> 18 yrs of age.\n* Patients diagnosed with stage I-IV breast cancer, who have not begun definitive therapy.\n* Patients undergoing screening mammograms for breast cancer.\n\nExclusion Criteria:\n\n* Patients with a history of a different cancer within the previous 3 years (except non melanoma skin cancer).\n* Any prior treatment (surgery, chemo, hormonal, radiation, biologics, etc.) for current cancer.\n* Any biopsy which resulted in the entire tumor tissue being removed.\n* History of previous breast cancer.\n* Patients unable to provide informed consent.\n* Patients with an abnormal screening mammogram.\n* Patients whose hormone receptor and\u002For HER2 status are not available.","FEMALE","18 Years",{"count":88,"type":89},500,"ESTIMATED","OBSERVATIONAL","Differential immunogenomic signatures from peripheral blood CD14 (phagocytic) and CD2 (non-phagocytic) cells have been associated with multiple cancers and disease states. In particular several large clinical studies at Immunis.AI have demonstrated robust immunogenomic signatures in early-stage prostate cancer. Immunis.AI therefore hypothesizes that a peripheral blood immunogenomic signature will identify patients with various stages of breast cancer from healthy negative controls.",[93,94],"Breast Cancer","Breast Cancer Female",[93,96],"Immunogenomics","NOT_YET_RECRUITING","2024-03-05",{"date":100,"type":101},"2024-03-06","ACTUAL",{"date":103,"type":89},"2025-09-01",{"date":105,"type":89},"2027-12-31",{"name":5,"class":6},1]